Conference Coverage
Conference Coverage
Global study to track COVID-19’s impact on the brain
The research will track and evaluate the short- and long-term impact of the coronavirus on the brain, including cognition, behavior, and function...
Conference Coverage
How often does risk-reducing salpingo-oophorectomy identify cancer?
In one study of women with BRCA mutations who underwent the procedure, about 3% received a cancer diagnosis.
Conference Coverage
Better continence rate gives robotic prostatectomy the edge
A large trial confirms early continence is better with a robotic rather than classical laparoscopic approach.
Conference Coverage
Higher death rate seen in cancer patients with nosocomial COVID-19
All-cause mortality was higher in cancer patients with hospital-acquired COVID-19 than in those with community-acquired COVID-19.
News
MIS-C is a serious immune-mediated response to COVID-19 infection
Multisystem inflammatory syndrome in children (MIS-C) is still a moving target because there is much still to learn about it.
Conference Coverage
Robotic renal surgery bests open partial nephrectomy
Fewer complications were seen during and after surgery when partial nephrectomy was performed using robotic assistance versus an open procedure....
Conference Coverage
CCC19, other registries help define COVID/cancer landscape
New data from CCC19 show an increased risk of death from COVID-19 among non-Hispanic black cancer patients and patients with hematologic...
News
Men occupy most leadership roles in medicine
In pediatrics, a specialty where approximately 70% of physicians are now women, there has been progress, according to an expert.
Conference Coverage
Intravesical BCG dosing frequency ‘critical’ in bladder cancer
Reducing the dosing frequency of bacillus Calmette-Guérin more than doubled the rate of disease recurrence.
Conference Coverage
PSMA PET/CT may be new ‘gold standard’ for prostate cancer staging
PSMA PET/CT was 27% more accurate than conventional imaging for detecting metastases and staging men with high-risk prostate cancer.